United States · Amendment · HAMDT
HAMDT 719 (116th)
An amendment numbered 9 printed in Part B of House Report 116-334 to require drug companies to disclose truthful and non-misleading pricing information about prescription drugs and biological products when they advertise these products directly to consumers.
Introduced
—
Last action
—
Status
On agreeing to the Finkenauer amendment (A009) Agreed to by voice vote.
Sponsors
Rep. Finkenauer, Abby [D-IA-1]
Subjects
Discovery layer
Source updated
8 February 2022
Records
Official amendment HAMDT 719 (116th) from United States at United States Congress. Status: On agreeing to the Finkenauer amendment (A009) Agreed to by voice vote..
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Leesvertaling
Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.
Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.
Sponsors
- Rep. Finkenauer, Abby [D-IA-1] · D · Sponsor
Related records
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/amendment/116th-congress/hamdt-719
- Open data entity: https://api.congress.gov/v3/amendment/116/hamdt/719
- us · 116-hamdt-719 · source updated 8 February 2022